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ABSTRACT
Survivin is a member of the inhibitor of apoptosis gene family that is
expressed in most human cancers and may facilitate evasion from apo-
ptosis and aberrant mitotic progression. Here, exposure of breast carci-
noma MCF-7 or cervical carcinoma HeLa cells to anticancer agents,
including Adriamycin, Taxol, or UVB resulted in a 4–5-fold increased
survivin expression. Changes in survivin levels after anticancer treatment
did not involve modulation of survivin mRNA expression and were inde-
pendent of de novo gene transcription. Conversely, inhibition of survivin
phosphorylation on Thr34 by the cyclin-dependent kinase inhibitor fla-
vopiridol resulted in loss of survivin expression, and nonphosphorylatable
survivin Thr343Ala exhibited accelerated clearance as compared with
wild-type survivin. Sequential ablation of survivin phosphorylation on
Thr34 enhanced tumor cell apoptosis induced by anticancer agents inde-
pendently of p53 and suppressed tumor growth without toxicity in a
breast cancer xenograft model in vivo. These data suggest that Thr34
phosphorylation critically regulates survivin levels in tumor cells and that
sequential ablation of p34cdc2 kinase activity may remove the survivin
viability checkpoint and enhance apoptosis in tumor cells.
INTRODUCTION
The ability of cells to evade apoptosis, or programmed cell death
(1), is a molecular trait perhaps common to all human cancers (2).
This results in aberrantly extended cell viability, which translates in
increased risk of transforming mutations, accelerated disease progres-
sion, and resistance to therapy (3). Among the regulators of apoptosis
involved in cancer, interest has been recently focused on survivin (4),
a member of the IAP3 gene family (5). Abundantly expressed during
embryonic development but undetectable in most normal adult tissues,
survivin is dramatically overexpressed in most human cancers and
correlates with abbreviated survival, unfavorable prognosis, resistance
to therapy, and accelerated rates of recurrences (4). Common molec-
ular alterations of cancer, including loss of p53 (6, 7), changes in
chromatin accessibility, i.e., demethylation (8), or gain of the survivin
locus on 17q25 (9), have been implicated in deregulation of survivin
gene expression in transformed cells (7). Survivin has been associated
with both cytoprotection and preservation of microtubule integrity (4),
and its expression in malignant cells may facilitate evasion from
apoptosis and promote aberrant mitotic progression, thus exacerbating
aneuploidy.
The possibility of exploiting the survivin pathway for cancer ther-
apy has been intensely investigated. In these studies, molecular an-
tagonists of survivin including antisense or dominant negative mu-
tants or generation of survivin-specific cytolytic T cells caused tumor
cell apoptosis, enhanced chemotherapy-induced cell death, and re-
sulted in anticancer activity in vivo (10–12). One of the critical
requirements for survivin function was recently identified in the
phosphorylation on Thr34 by the mitotic kinase p34cdc2-cyclin B1
(13), and a phosphorylation-mimetic survivin mutant strongly inhib-
ited p53-induced apoptosis (6). This step has also been exploited for
anticancer therapy, and inducible expression (14) or adenoviral deliv-
ery (15) of nonphosphorylatable survivin Thr343Ala prevented
phosphorylation of endogenous survivin, which resulted in caspase-
9-dependent apoptosis and anticancer activity in vivo (14, 15). How-
ever, the mechanism(s) by which Thr34 phosphorylation participates
in survivin function has not been elucidated.
Using flavopiridol as a model of a Cdk inhibitor (16), we found that
phosphorylation on Thr34 is required to maintain survivin expression/
stability in cancer cells and that ablation of p34cdc2 kinase in mitoti-
cally arrested cells results in loss of survivin levels and dramatic
enhancement of chemotherapy-induced anticancer activity in vivo.
MATERIALS AND METHODS
Cell Cultures, Proteins, and Antibodies. Breast carcinoma MCF-7 cells
carrying wild-type p53 or cervical carcinoma HeLa cells with functionally
inactivated p53 (American Type Culture Collection, Manassas, VA) were
incubated with vehicle (DMSO), Taxol (2 M; Sigma, St. Louis, MO), Ad-
riamycin (100 nM, Sigma), or cisplatin (3 M; Sigma) or exposed to UVB
irradiation at 50 or 300 J/m2. To pharmacologically target survivin phosphor-
ylation by p34cdc2 (13), cells were incubated with increasing concentrations of
vehicle or the Cdk inhibitor flavopiridol (1–1000 nM) for 48–72 h at 37°C and
analyzed for protein expression by Western blotting or apoptosis by PI staining
and flow cytometry, as described previously (17). Wild-type survivin or
survivin(T34A) were expressed in Escherichia coli as glutathione S-transferase
fusion proteins, as described previously (13). Antibodies to p34cdc2 or bcl-2
were obtained from PharMingen (San Diego, CA) and R&D, respectively. An
antibody to -actin was from Sigma, and an antibody to MPM-2 mitotic
phosphoproteins was from Upstate Biotechnology (Lake Placid, NY). Affinity-
purified antibodies to survivin or Thr34-phosphorylated survivin (-survivin
T34*) were described previously (13).
Northern Hybridization, Reverse Transcription-PCR, Immunoprecipi-
tation, and Kinase Assay. Total RNA was extracted from MCF-7 cells at
various time intervals after Adriamycin treatment and hybridized with 32P-
labeled survivin cDNA as described previously (18). Radioactive bands were
detected by autoradiography. Alternatively, total RNA was reverse-transcribed
with Superscript II and amplified with survivin-specific primers, and products
were visualized by ethidium bromide-stained agarose gels. Amplification of
glyceraldehyde-3-phosphate dehydrogenase served as an internal control. Sur-
vivin or p34cdc2 was immunoprecipitated from detergent-solubilized HeLa or
MCF-7 cell extracts as described previously (13). For kinase assays, baculo-
virus-expressed p34cdc2-cyclin B1 was incubated with vehicle or flavopiridol
(100 nM) and mixed with histone H1 (1 g), wild-type survivin or
survivin(T34A) (6 g) in the presence of 10 Ci of [-32P]ATP (Amersham).
After a 30–45-min reaction at 30°C, radioactive bands were separated by
SDS-gel electrophoresis and visualized by autoradiography, as described pre-
viously (13). In other experiments, endogenous survivin was immunoprecipi-
tated from flavopiridol-treated HeLa cells (0–500 nM), and immune complexes
were analyzed by Western blotting with antibodies to p34cdc2 (1 g/ml),
survivin (2 g/ml), or survivin T34* (5 g/ml). For cycloheximide block
experiments, subconfluent cultures of MCF-7 cells were transfected with
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GFP-survivin or GFP-survivin(T34A) by LipofectAMINE, as described. After
a 16-h interval, cells were incubated with cycloheximide (20 M) to prevent
further expression of transfected plasmids plus the broad-spectrum caspase
inhibitor Z-VAD-fmk (20 M) to prevent loss of cell viability associated with
survivin(T34A) expression. Aliquots of the various cultures were harvested
0–120 h after cycloheximide block and analyzed for expression of GFP-
containing fusion proteins by Western blotting with an antibody to GFP.
Survivin Promoter-Luciferase Reporter Expression. MCF-7 cells
(1–2  105 cells/well) were transfected with a minimal survivin promoter
upstream of a luciferase reporter gene (pLuc-cyc1.2) by LipofectAMINE as
described previously (18). Cells were treated with Taxol or Adriamycin or
exposed to UVB irradiation as described, and luciferase activity was deter-
mined after 0–24 h of incubation at 37°C on a Lumat luminometer (LB9510),
with normalization to -galactosidase activity.
MPM-2 Mitotic Phosphoepitope Expression. For detection of mitotic
phosphoproteins (19), MCF-7 cells (1–2 105 cells/60-mm dish) were treated
with Taxol or Adriamycin or exposed to UVB irradiation as described and
cultured for 0, 8, 16, 24, or 36 h at 37°C. Cells were fixed in 70% ethanol and
labeled with MPM-2 antibody (6 g/ml) followed by the addition of goat
antimouse FITC (Boehringer Mannheim) for 1 h at 22°C in the presence of 5
g/ml PI containing 50 g/ml RNase A. Samples were analyzed on a FAC-
Scan (Becton Dickinson, Mountain View, CA) using CellQuest software.
Xenograft Breast Cancer Model. All experiments involving animals were
approved by the Institutional Animal Care and Use Committee. Breast carci-
noma MCF-7 xenografts were developed in 5-week-old female CB.17 SCID/
beige mice (Taconic Farms, Germantown, NY) as described previously (15).
Each mouse received 2.5 106 exponentially growing MCF-7 cells (in 100 l
of sterile 1 PBS) s.c. in the right flank area. Tumors became palpable (25–75
mm3) within 5 days of tumor cell injection, after which groups of five animals
were randomized and assigned to different treatment groups. Tumor size was
measured in three dimensions with a caliper. Animals were sacrificed once
their tumor burden reached 3000 mm3. Animals were given i.p. injections with
Adriamycin alone (1.0, 2.0, or 4.0 mg/kg), flavopiridol alone (15 mg/kg), or
the sequential combination of Adriamycin/flavopiridol for two consecutive
days, each divided by a day with no treatment. For single-agent treatment,
vehicle was given in place of Adriamycin or flavopiridol with the same
schedule. Each complete cycle was separated by 2 days without treatment.
Statistical Analysis. All in vitro experiments were repeated at least three
times unless otherwise indicated. For in vivo studies, each X value (time)
shows the fraction still alive. We calculated survival fractions using the
product limit or Kaplan-Meier method. The survival curves were compared
using the log-rank test. This test generates a P value testing the null hypothesis
that the survival curves are identical in the overall populations.
RESULTS
Regulation of Survivin Levels by Thr34 Phosphorylation. To
target survivin phosphorylation on Thr34, we used the broad-spectrum
Cdk inhibitor flavopiridol (16). Incubation of baculovirus-expressed
p34cdc2-cyclin B1 with 100 nM flavopiridol abolished phosphorylation
of 32-kDa histone H1 and wild-type survivin in a kinase assay in
vitro (Fig. 1A). In contrast, no phosphorylation of survivin(T34A) by
p34cdc2-cyclin B1 was observed in the presence or absence of fla-
vopiridol (Fig. 1A). Treatment of HeLa cells with flavopiridol resulted
in concentration-dependent inhibition of survivin phosphorylation on
Thr34 by Western blotting of survivin immunoprecipitates with a
Thr34-phosphospecific antibody (-survivin T34*; Fig. 1B). Inhibi-
Fig. 1. Regulation of survivin levels by Thr34
phosphorylation. A, kinase assay. Wild-type sur-
vivin (WT), histone H1 (H1), or phosphorylation-
defective survivin(T34A) (T34A) were incubated
with baculovirus-expressed p34cdc2-cyclin B1 and
[-32P]ATP in a kinase assay in the presence or
absence of flavopiridol. Radioactive bands were
detected by autoradiography. B, inhibition of sur-
vivin phosphorylation on Thr34 by flavopiridol in
vivo. Endogenous survivin was immunoprecipi-
tated (IP) from HeLa cells treated with the indi-
cated concentrations of flavopiridol for 24 h. The
immune complexes were analyzed by Western
blotting (WB) with an antibody to Thr34-phosphor-
ylated survivin (-survivin T34*, top panel) or
with an antibody to survivin (-survivin, bottom
panel) followed by chemiluminescence. C, regula-
tion of endogenous survivin levels by flavopiridol.
HeLa cells were treated with the indicated concen-
trations of flavopiridol for 48 h and analyzed for
expression of survivin (top panel) or -actin (bot-
tom panel) by Western blotting. D, effect of genis-
tein or TNF- on survivin levels. The experimental
conditions are the same as those in C. Modulation
of survivin expression after a 48-h treatment in the
presence of genistein or TNF- was assessed by
Western blotting. E, kinetics of survivin expression
after cycloheximide block. MCF-7 cells were
transfected with cDNAs encoding wild-type sur-
vivin (WT) or phosphorylation-defective survivin
Thr343Ala mutant (T34A) fused to GFP. After a
16-h incubation, cultures were incubated with 20
M cycloheximide plus 20 M Z-VAD-fmk, har-
vested at the indicated time intervals, and analyzed
with antibodies to GFP or -actin by Western blot-
ting. For all panels, relative molecular mass mark-
ers in kDa are shown on the left.
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tion of survivin phosphorylation on Thr34 was also associated with
progressive loss of survivin expression at increasing flavopiridol
concentrations by Western blotting with an antibody to survivin
(Fig. 1B). Consistent with these observations, exposure of HeLa cells
to flavopiridol resulted in progressive decrease in endogenous sur-
vivin levels by Western blotting (Fig. 1C). In control experiments,
flavopiridol did not affect the expression of antiapoptotic Bcl-2,
whereas the flavone genistein, which does not inhibit Cdk activity
(20), or TNF- did not affect survivin expression by Western blotting
(data not shown; Fig. 1D). To confirm that Thr34 phosphorylation
influenced survivin stability, we used cycloheximide block in MCF-7
cells transfected with survivin cDNAs fused to GFP. To overcome
apoptosis induced by expression of survivin(T34A) (13), a broad-
spectrum caspase inhibitor, Z-VAD-fmk (20 M), was also added.
MCF-7 cells transfected with wild-type survivin exhibited time-
dependent expression of a GFP-containing fusion protein that re-
mained sustained for up to 96 h after transfection by Western blotting
(Fig. 1E). In contrast, nonphosphorylatable survivin(T34A) was rapidly
cleared from MCF-7 cells and nearly entirely depleted 72 h after
transfection (Fig. 1E).
Modulation of Survivin Expression by Anticancer Agents. To
determine the potential relevance of targeting survivin phosphoryla-
tion on Thr34 for tumor cell apoptosis, we first analyzed survivin
levels in breast carcinoma MCF-7 cells treated with various anticancer
drugs. Exposure of MCF-7 cells to Adriamycin (100 nM), Taxol (2
M), or 50 J/m2 UVB irradiation resulted in a 4–5-fold increase in
survivin expression by Western blotting (Fig. 2A). In contrast, cispla-
tin (3 M) or 300 J/m2 UVB irradiation did not significantly affect
survivin levels in MCF-7 cells (Fig. 2A). The increase in survivin
expression by anticancer drugs was not accompanied by changes in
survivin mRNA levels at various time intervals after Adriamycin
treatment by Northern hybridization (Fig. 2B). Similar results were
obtained by reverse transcription-PCR amplification of survivin tran-
script(s) in Adriamycin-treated MCF-7 cells (data not shown). When
directly analyzed for potential changes in survivin gene expression,
treatment of MCF-7 cells with the various anticancer drugs resulted in
significant suppression of survivin promoter activity, as determined
by analysis of MCF-7 cells transfected with a minimal survivin
promoter upstream of a luciferase reporter gene (Fig. 2C).
Role of Thr34 Phosphorylation on Survivin Levels during An-
ticancer Treatment. Because increased survivin levels induced by
anticancer treatment did not involve changes in survivin mRNA or
promoter activity, we investigated a potential role of Thr34 phosphor-
ylation in regulating survivin stability/expression (Fig. 1) under these
conditions. In a kinase assay, p34cdc2 immunoprecipitated from
Adriamycin-treated cells phosphorylated 32-kDa histone H1 (Fig.
3A). Under these experimental conditions, p34cdc2 immunoprecipi-
tates from Adriamycin-treated cells also contained a phosphorylated
16.5-kDa band, which was identified as survivin by Western blot-
ting with an antibody to survivin (Fig. 3A) and in agreement with the
physical association of survivin with p34cdc2 (13). The presence of
functional p34cdc2 activity in Adriamycin-treated cells correlated with
the presence of a residual MCF-7 cell population (20–25%) exhibiting
elevated MPM-2 mitotic phosphoepitope expression (Fig. 3B), in
agreement with previous observations (21).
Suppression of Thr34 Phosphorylation of Survivin Enhances
Anticancer Treatment. For the role of Thr34 phosphorylation in
stabilizing survivin levels during anticancer treatment, we next asked
whether sequential ablation of p34cdc2 kinase activity could function
to reduce survivin expression and enhance tumor cell apoptosis.
Treatment of MCF-7 cells with 100 nM Adriamycin or 50 J/m2 UVB
irradiation resulted in a 4.2- and 3.1-fold increase in survivin expres-
sion, respectively, by Western blotting (Fig. 4A) and in agreement
with the data presented above (Fig. 2). At the concentration and time
intervals used, flavopiridol alone did not significantly affect survivin
levels in MCF-7 cells (Fig. 4A). In contrast, sequential treatment of
MCF-7 cells with Adriamycin or UVB irradiation for 18 h followed
by flavopiridol for 72 h significantly inhibited the increase in survivin
expression, which approached background levels of untreated cultures
(Fig. 4A). Sequential flavopiridol treatment was also associated with
suppression of survivin phosphorylation on Thr34 by Western blotting
of survivin immunoprecipitates with a Thr34-phosphospecific anti-
body (Fig. 4B). Under these experimental conditions, loss of survivin
expression in sequentially treated cultures was associated with signif-
icantly enhanced apoptosis induced by UVB (2%, 5%, and 12%) and
Adriamycin (2%, 3%, and 10%) to 12%, 26%, and 46% and 22%,
45%, 60%, respectively, as compared with single-agent treatment
alone (Fig. 4C).
Fig. 2. Modulation of survivin expression by anticancer agents. A, Western blot.
MCF-7 cells were treated with Adriamycin (100 nM), Taxol (2 M), cisplatin (3 M), or
exposed to UVB irradiation (50 or 300 J/m2) and analyzed for expression of survivin (top
panel) or -actin (bottom panel) by Western blotting (WB). B, Northern hybridization.
Total RNA was extracted from Adriamycin-treated MCF-7 cells at the indicated time
intervals and hybridized with a [32P]dCTP-labeled survivin cDNA (top panel). Relative
band intensities were normalized by densitometry using 28S RNA as internal control
(bottom panel). C, promoter analysis. MCF-7 cells were transfected with a minimal
survivin promoter (pLuc-cyc1.2) upstream of a luciferase reporter gene, treated with the
various anticancer regimens, and analyzed for luciferase activity at the indicated time
intervals. Luciferase activity was normalized to -galactosidase activity used as an
internal control. Data represent the average of two independent experiments.
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Sequential Inhibition of Survivin Phosphorylation on Thr34 as
a Novel Anticancer Regimen, in Vivo. We next asked whether
sequential suppression of Thr34 phosphorylation could provide an
effective anticancer regimen in vivo. Treatment of SCID/bg mice
bearing MCF-7 xenograft tumors (70–100 mm3) with Adriamycin (2
mg/kg) or flavopiridol (15 mg/kg) alone did not affect tumor growth,
as compared with animals given vehicle (Fig. 5A). In contrast, se-
quential combination therapy of Adriamycin (2 mg/kg/day over 2
days) followed by flavopiridol (15 mg/kg/day over 2 days) arrested
tumor growth and resulted in indefinite survival of all treated animals
(Fig. 5A). Significantly increased survival (P  0.0001) was also
observed upon suspension of sequential Adriamycin-flavopiridol
treatment, when tumors exhibited de novo growth comparable to that
of animals receiving single anticancer regimens (Fig. 5B). Mice
treated with the sequential administration of Adriamycin-flavopiridol
did not exhibit overt signs of systemic toxicity (weight loss, diarrhea,
and so forth).
DISCUSSION
In this study, we have shown that survivin levels in tumor cells are
critically regulated by phosphorylation on Thr34. Conversely, timed
suppression of survivin phosphorylation on Thr34 by a broad-
spectrum Cdk inhibitor, flavopiridol, resulted in loss of survivin
expression, enhanced chemotherapy-induced apoptosis, and anti-
cancer activity in vivo.
Protein phosphorylation has been implicated in the regulation of
cell death pathways, influencing subcellular localization (22), cyto-
protection (23, 24), and cell cycle transitions (25, 26). There is
also ample precedent for a role of phosphorylation in controlling
stability/expression of cell death regulators. In this context, phospho-
rylation of bcl-2 on Thr56, Thr74, and Ser87 (27) or of p53 on Ser15 and
Ser37 (28) has been implicated in preventing ubiquitin-dependent
proteasome degradation. In the survivin crystal structure (29), Thr34 is
ideally positioned in an acidic knuckle to regulate the binding of
potential client proteins controlling survivin stability and/or ubiquitin-
dependent degradation. For IAP family proteins, including survivin
(30), ubiquitin-dependent proteasome destruction has been recognized
as a critical mechanism to regulate protein levels, influencing
IAP-dependent cytoprotection (31). This suggests that the strong
anticancer activity associated with overexpression of nonphosphory-
latable survivin (T34A) may derive from inhibition of endogenous
survivin phosphorylation (14), followed by fall of survivin levels and
tumor cell apoptosis. A similar phenotype has been observed after
treatment with survivin antisense oligonucleotides, which resulted in
suppression of endogenous survivin levels, spontaneous tumor cell
apoptosis, and enhancement of anticancer regimens in vitro and in
vivo (10, 12, 17, 32).
Because adenoviral delivery of dominant negative survivin (T34A)
may have only limited applications for cancer therapy (15), we tar-
Fig. 4. Timed ablation of survivin phosphorylation on Thr34 enhances genotoxic
stress-induced apoptosis. A, modulation of survivin expression. MCF-7 cells (2  105
cells/ml) were treated with Adriamycin (100 nM) or exposed to UVB irradiation (50 or 300
J/m2) in the presence or absence of flavopiridol (100 nM) for 18 h and analyzed for
expression of survivin or -actin by Western blotting. Band intensities were normalized
by densitometry and expressed as fold increase over control. B, inhibition of survivin
phosphorylation on Thr34. Survivin was immunoprecipitated from MCF-7 cells treated as
described in A, and immune complexes were analyzed by Western blotting (WB) with an
antibody to survivin or Thr34-phosphorylated survivin (-survivin T34*). C, enhancement
of apoptosis. The experimental conditions are as described in A, except that MCF-7 cells
treated with the indicated anticancer agents alone or in sequential combination with
flavopiridol were analyzed for DNA content by PI staining and flow cytometry. Results
represent the mean  SD of three different experiments.
Fig. 3. Regulation of Thr34 phosphorylation by Adriamycin treatment. A, kinase assay.
MCF-7 cells were treated with Adriamycin (100 nM) for 0–48 h at 37°C, followed by
immunoprecipitation of p34cdc2 and kinase assay in the presence of histone H1. p34cdc2
immunoprecipitates were analyzed by Western blotting (WB) with an antibody to survivin
followed by chemiluminescence. B, MPM-2 expression. MCF-7 cells treated with the
indicated anticancer agents were harvested after 0–36 h culture, stained with a MPM-2
antibody, and analyzed by flow cytometry.
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geted the step of survivin phosphorylation on Thr34 using a broad-
spectrum kinase inhibitor, flavopiridol. Kinase inhibitors, including
Cdk antagonists, have recently emerged as promising anticancer
agents (33, 34), and flavopiridol has entered clinical trials (35, 36) for
its ability to trigger apoptosis (37, 38) and exert anticancer activity in
tumor models (35, 39). Despite intense investigation, the molecular
basis of flavopiridol-mediated anticancer activity has not been com-
pletely elucidated and may involve mechanisms unrelated to p34cdc2
inhibition, including global suppression of gene transcription by in-
terfering with Cdk9/cyclin T function (40). In addition, flavopiridol
functions as a relatively broad inhibitor of various Cdks as well as
non-cell cycle-regulated kinases (40), thus potentially producing mul-
tiple effects on cell cycle progression, gene expression, or general
signaling pathways. Despite these potential limitations, it is tempting
to speculate that one of the mechanisms by which flavopiridol may
exert its proapoptotic function may involve loss of survivin expression
due to suppression of phosphorylation on Thr34. This model may be
consistent with recent observations of the ability of flavopiridol to
reduce the expression of other IAP family proteins (41), suggesting
that global repression of cytoprotective molecules, including survivin,
may contribute to flavopiridol-mediated apoptosis in vivo.
Whereas flavopiridol alone was sufficient to induce loss of survivin
expression and apoptosis, the most significant enhancement of tumor
cell apoptosis was obtained in sequential combination with selected
chemotherapeutic agents. In this context, anticancer drugs inducing
G2-M arrest with elevated (taxanes) or residual (Adriamycin) p34cdc2
kinase activity and detectable MPM-2 phosphoepitope expression
were shown to cause Thr34 phosphorylation and increased survivin
levels. Despite the known cell cycle periodicity of survivin expression
at mitosis (18), modulation of survivin levels by anticancer drugs did
not involve changes in survivin mRNA or promoter function. In fact,
transcription of the survivin gene was actually repressed by anticancer
agents, which is consistent with similar findings observed with other
G2-M-regulated genes containing, like survivin, cell-cycle dependent
element (CDE)/cell cycle homology region (CHR) promoter elements
(42). Whether this pathway of survivin protein stabilization by anti-
cancer drugs may facilitate the insurgence of chemoresistance, which
has been consistently associated with the presence of survivin in
tumors, in vivo (4) is currently not known. However, sequential
ablation of survivin phosphorylation on Thr34 following Adriamycin
treatment resulted in enhanced tumor cell apoptosis, in agreement
with previous observations (43), and significantly increased antican-
cer activity in a xenograft breast cancer model in vivo. Similar results
were obtained when p34cdc2 kinase activity was sequentially sup-
pressed after Taxol treatment, consistent with dephosphorylation of
survivin on Thr34 in mitotically arrested cells and apoptosis (44). On
the other hand, UVB-induced G2-M arrest resulted in increased sur-
vivin expression despite the absence of MPM-2 phosphoepitope ex-
pression and lack of p34cdc2 kinase activity, suggesting that p34cdc2
may not be the only kinase inhibited by flavopiridol and required for
survivin stability at G2-M.
The findings described here may have practical implications for
anticancer strategies. A simplistic model that survivin may be exclu-
sively involved in mitotic regulation (45) has been discounted by
overwhelming experimental evidence demonstrating that survivin tar-
geting provides a viable anticancer approach for potently inducing
apoptosis in vivo (4). Sequential therapy has recently emerged as a
strategy to rationally improve the efficacy of anticancer combination
therapy. Taken together, our findings may provide a molecular basis
for the previously reported efficacy of flavopiridol to enhance
chemotherapy-induced apoptosis in a strict sequence-dependent man-
ner (46, 47) and the recent implementation of sequential combination
therapy using flavopiridol in clinical protocols (48). Indeed, results
from Phase II clinical trials using flavopiridol as a single-agent
treatment were essentially negative in a variety of solid tumors with
unacceptable systemic toxicity. Consistent with the approach pre-
sented here, this has prompted a strategy for combining flavopiridol
with established chemotherapeutic regimens, i.e., taxanes, for clinical
treatment protocols (48). For the emerging role of kinase inhibitors,
including Cdk antagonists, in cancer treatment (33, 34) and the
extreme sensitivity of tumor cells to manipulation of the survivin
pathway (4), sequential ablation of p34cdc2 kinase activity after ad-
ministration of genotoxic agents (this study) or spindle poisons, i.e.,
taxanes (44), may provide a rational approach to destabilize survivin
levels in tumor cells and enhance the efficacy of common anticancer
regimens in patients.
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